PTPN11 and cancer: Subsequently, another SHP2 degrader 63 (R1-5C, Fig. 17) developed by conjugating RMC-4550 with pomalidomide was reported.117 The degrader 63 (R1-5C) exhibited highly selective SHP2 degradation with low concentration, suppressed MAPK signaling, and inhibited cancer cell growth.